FASN and prostate carcinoma: In recent years, a large number of studies have found that FASN is overexpressed in solid tissue tumors such as esophageal cancer, breast cancer, prostate cancer, ovarian cancer, endometrial cancer, gastric cancer, malignant melanoma, and is associated with the malignant phenotype and poor clinical characteristics of tumors [43, 67–70].